Humana Covers Barostim for 5.2M Medicare Advantage Members Starting May 2026
CVRX•CVRx secured Medicare Advantage coverage from Humana for its Barostim heart failure therapy, covering approximately 5.2 million members across 46 states effective May 1, 2026. The policy applies to FDA-approved indications and BENEFIT-HF trial participants and follows January reimbursement wins including Category I CPT codes and CMS IDE coverage.
1. Humana Medicare Advantage Coverage Policy
CVRx announced that Humana will cover Barostim therapy for heart failure patients under its Medicare Advantage program starting May 1, 2026. This marks the first dedicated coverage policy for Barostim and extends benefits to approximately 5.2 million members across 46 states.
2. Coverage Scope and Clinical Trials
The policy includes patients meeting current FDA-approved indications and participants in the BENEFIT-HF trial, which is evaluating Barostim in an expanded heart failure population. Coverage for trial enrollees supports enrollment and may accelerate data collection for long-term therapy outcomes.
3. Earlier Reimbursement Developments
On January 1, 2026, CVRx secured Category I CPT codes for the Barostim procedure and obtained CMS Category B IDE coverage for BENEFIT-HF trial participants, enhancing reimbursement clarity. These developments underpin CVRx's commercial strategy and bolster payer confidence.
